NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed strong financial performance with a 15% revenue growth, improved gross margin, and increased net income. Despite operating expense growth, the company demonstrated effective cost management and operational efficiency. The strategic plan outlines revenue growth through expanded insurance coverage and commercial footprint. The absence of negative Q&A insights and the company's liquidity position further support a positive outlook. However, the lack of market cap data limits the prediction's accuracy.
Key Financial Performance
Revenue Revenue for Q1 2026 was $12.5 million, representing a 15% increase year-over-year. This growth was driven by strong demand for our flagship product and expansion into new markets.
Gross Margin Gross margin improved to 65%, up from 60% in Q1 2025. The improvement was attributed to cost efficiencies and higher production volumes.
Operating Expenses Operating expenses increased to $7 million, a 10% rise compared to Q1 2025. This was due to increased investment in R&D and marketing efforts.
Net Income Net income for the quarter was $2 million, up from $1.5 million in Q1 2025, reflecting a 33% increase. This was primarily due to higher revenues and improved operational efficiency.
Cash Flow Operating cash flow was $3.5 million, a 40% increase year-over-year, driven by improved collections and operational performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from expectations. This includes risks related to market conditions, competitive pressures, regulatory hurdles, supply chain disruptions, economic uncertainties, and strategic execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Behnam Shamsian
CEO Director
CEO Tim
CFO NeurAxis
Capital Group
Chase Knickerbocker
Chief Financial
Conference Instructions
Craig Hallum
Director Timothy
Division EDT
EDT day
Financial Officer
Group LLC
Hallum Capital
Instructions event
Investor Relations
Knickerbocker Craig
LLC Research
NeurAxis conclusion
Officer Chase
President CEO
Relations President
Results Conference
Shamsian Investor
Tim CFO
Timothy Chief
conference Investor
event conference
instruction question
question Today
question instruction
NRXS Transcript
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call revealed strong financial performance with a 15% revenue growth, improved gross margin, and increased net income. Despite operating expense growth, the company demonstrated effective cost management and operational efficiency. The strategic plan outlines revenue growth through expanded insurance coverage and commercial footprint. The absence of negative Q&A insights and the company's liquidity position further support a positive outlook. However, the lack of market cap data limits the prediction's accuracy.
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call presented mixed signals. While there's optimism around future revenue growth and the new CPT code, immediate financial performance showed declining margins and increased losses. The Q&A revealed strong adoption among some hospitals but also highlighted barriers like prior authorization delays and unclear guidance. The lack of specific revenue guidance and increased operating expenses adds uncertainty. Overall, the strategic plans for 2026 seem positive, but current challenges temper immediate stock price impact, leading to a neutral sentiment.
NeurAxis, Inc. (NRXS) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call reveals mixed sentiments. Basic financial performance shows revenue growth but also increased losses and expenses. Product updates, like the RED launch, face adoption challenges, and there's uncertainty in market strategy due to reliance on the new CPT code. The Q&A highlights cautious optimism but lacks concrete details, leading to investor uncertainty. Despite positive long-term prospects, short-term hurdles and management's vague responses temper enthusiasm. Overall, the sentiment remains neutral, expecting minimal stock price movement in the short term.
NeurAxis, Inc. (NRXS) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call revealed strong revenue growth (39% in Q1 2025) and a significant increase in unit sales (58% YoY), despite a slight decline in gross margin. Operating expenses and losses decreased, showing improved cost management. The Q&A highlighted positive responses from insurance payers and potential for expanded insurance coverage, which could boost future sales. While there are uncertainties in policy writing speed and coverage timelines, the overall sentiment is positive due to revenue growth, cost management, and optimistic insurance coverage outlook.
NRXS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
